Home / Manufacturing Compliance
Exhibit 1
Evidence of cGMP/cGxP Non-Compliance in Manufacture and Distribution of the Biological Materials Marketed as "Covid-19 Vaccines"
Current Good Manufacturing Practice (cGMP) rules set the minimum standards for how drugs and biologics are made, tested, labeled and released. This exhibit reviews the public record on whether those standards were met for COVID-19 vaccines.
What the exhibit covers
- Executive summaryp. 2
- Pharmaceutical industry regulations: backgroundp. 2
- Evidence of noncompliance with cGMP for COVID-19 vaccinesp. 4
- Evidence of deaths and injury worldwidep. 4
- Direct evidence of non-compliance with cGMPp. 4
- Independent testing of vial contents worldwidep. 5
- 33 commercial Pfizer batches manufactured before EUA/CMA approvalsp. 7
- Batch variability observed in the VAERS databasep. 9
- mRNA integrity and genetic material impuritiesp. 10
- No tests for conformity to label at the unit dose levelp. 12
- No serialization at the unit dosep. 13
Attachments
Attachments are listed in the order they appear in the exhibit.
Benzi Cipelli et al., blood microscopy (proof)
Exhibit reference 2, "Evidence of harm from countermeasures." Blood samples from injected individuals compared with injection-free controls. Full document.
Related analysis
cGMP evidence summary: batch variability, inspection findings, unit-dose testing and serialization
Our summary of Sasha Latypova's October 2022 TrialSite News analysis, which covers many of the same topics as this exhibit, with links to the FDA inspection records it cites.
About the full document. The complete exhibit, with all attachments, will be posted here as a PDF. Until then you can request a copy by email.